A year af­ter em­bark­ing on a new HQ and man­u­fac­tur­ing site, Ab­Cellera starts sec­ond phase of its build­out

A year ago, Cana­di­an an­ti­body biotech Ab­Cellera broke ground on the first phase of its head­quar­ters ex­pan­sion in Van­cou­ver, along with a new man­u­fac­tur­ing site in the city. Now, the com­pa­ny is forg­ing ahead with the sec­ond part of the project.

The com­pa­ny has bro­ken ground on the next phase build­ing out what will ul­ti­mate­ly be a 380,000-square-foot cam­pus. Ab­Cellera hopes to in­clude lab and of­fice space to sup­port its work in an­ti­body de­vel­op­ment.

Mur­ray Mc­Cutcheon

Ab­Cellera’s SVP of cor­po­rate de­vel­op­ment, Mur­ray Mc­Cutcheon, told End­points News in an in­ter­view that the new phase is crit­i­cal to es­tab­lish­ing not just greater ca­pac­i­ty but al­so ca­pa­bil­i­ties for wider an­ti­body dis­cov­ery and de­vel­op­ment.

“We are on a mis­sion now to in­te­grate ca­pa­bil­i­ties for­ward, to in­clude Trans­la­tion­al Sci­ences, process de­vel­op­ment, to sup­port, CMC, GMP man­u­fac­tur­ing and ul­ti­mate­ly in­te­grate all of these ca­pa­bil­i­ties to­geth­er so that our part­ners have a seam­less ca­pa­bil­i­ty with us to progress their pro­grams, right from tar­get through to the clin­ic,” Mc­Cutcheon told End­points.

The head­quar­ters ex­pan­sion comes as the com­pa­ny has grown to around 450 peo­ple, with 125 be­ing brought on in the last 12 months. The ex­pan­sion will help house sev­er­al hun­dred more em­ploy­ees in the fu­ture, Ab­Cellera says. The first phase of the project is still on track to be com­plet­ed next year, with the sec­ond ex­pect­ed to be fin­ished in 2025.

While the ex­act cost of the fa­cil­i­ty was not dis­closed, Mc­Cutcheon em­pha­sized that the com­pa­ny has more than $1 bil­lion on its bal­ance sheet, which clears the way for the com­pa­ny to in­vest in long-term projects.

While the new head­quar­ters is a ma­jor piece of Ab­Cellera’s fu­ture, it is al­so mak­ing good on build­ing out a new man­u­fac­tur­ing fa­cil­i­ty as well. Last year, the com­pa­ny an­nounced it would con­struct a 130,000-square-foot man­u­fac­tur­ing fa­cil­i­ty in a near­by dis­trict in Van­cou­ver. That project is es­ti­mat­ed to be com­plet­ed in 2024.

Mc­Cutcheon not­ed that man­u­fac­tur­ing plays a role in its new head­quar­ters too, as the two fa­cil­i­ties will share peo­ple and ma­te­ri­als to en­sure it’s close­ly in­te­grat­ed with the rest of the com­pa­ny’s op­er­a­tions.

“And that is a key part of our whole ap­proach here, to en­sure that we’re bring­ing forth mol­e­cules that have the right prop­er­ties to be de­vel­opable and man­u­fac­turable. And we’re able to in­te­grate seam­less­ly our dis­cov­ery and de­vel­op­ment ef­forts in­to the man­u­fac­tur­ing set­ting. So, this head­quar­ters ex­ten­sion sup­ports that over­all ap­proach,” he said.

Ab­Cellera has been tapped by sev­er­al ma­jor play­ers in the past cou­ple of years, in­clud­ing Eli Lil­ly and Mod­er­na dur­ing the height of Covid-19. One of its most re­cent part­ner­ships saw Ver­sant and Ab­Cellera be­gin­ning to work to­geth­er, but the specifics of the part­ner­ship were few.

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

What kind of PhI­Ib da­ta is worth $4B cash? Take­da’s Andy Plump has some thoughts on that

A few months back, when Takeda caused jaws to drop with its eye-watering $4 billion cash upfront for a mid-stage TYK2 drug from Nimbus, it had already taken a deep dive on the solid Phase IIb data Nimbus had assembled from its dose-ranging study in psoriasis.

Now, it’s rolling that data out, eager to demonstrate what inspired the global biopharma to go long in a neighboring, but new, disease arena for the pipeline. And the most avid students of the numbers will likely be at Bristol Myers Squibb, who will have a multi-year head start on pioneering the TYK2 space with Sotyktu (deucravacitinib) as Takeda makes its lunge for best-in-class status.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

FDA warns Proc­ter & Gam­ble over NyQuil la­bel's in­gre­di­ent list­ings

The FDA on Tuesday released a warning letter sent earlier this month to the Mason, OH-based site of Procter & Gamble Manufactura, raising questions about the list of ingredients on the label and in the electronic filing.

The warning says that for P&G’s over-the-counter Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion, there’s a “mismatched” list of active ingredients between the labeling and the electronic listing file. The listing file for the active ingredients did not match the active ingredients in the electronic file.

FDA in­di­cates will­ing­ness to ap­prove Bio­gen ALS drug de­spite failed PhI­II study

Ahead of Wednesday’s advisory committee hearing to discuss Biogen’s ALS drug tofersen, the FDA appeared open to approving the drug, newly released briefing documents show.

Citing the need for flexibility in a devastating disease like ALS, regulators signaled a willingness to consider greenlighting tofersen based on its effect on a certain protein associated with ALS despite a failed pivotal trial. The documents come after regulatory flexibility was part of the same rationale the agency expressed when approving an ALS drug last September from Amylyx Pharmaceuticals, indicating the FDA’s openness to approving new treatments for the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

The UK’s Medicines and Healthcare products Regulatory Agency is now reviewing Novo Nordisk’s marketing violation that resulted in its loss of UK trade group membership last week. Novo Nordisk was suspended on Thursday from the Association of the British Pharmaceutical Industry (ABPI) for two years after an investigation by its regulatory arm found the pharma broke its conduct rules.

MHRA said on Tuesday that its review of the Prescription Medicines Code of Practice Authority (PMCPA) investigation is standard practice. An MHRA spokesperson emphasized in an email to Endpoints News that the situation with Novo Nordisk is “incredibly rare” while also noting ABPI took “swift and proportionate action.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Growth hor­mone from No­vo Nordisk is in short­age over man­u­fac­tur­ing de­lays

Novo Nordisk’s growth hormone Norditropin is in shortage because of manufacturing delays, according to an FDA site that tracks drug shortages as well as the American Society of Health-System Pharmacists’ shortages list.

The FDA has shortages of the drug listed for its 5, 10, 15 and 30 mg doses, while the pharmacists’ group, also known as ASHP, reported shortages of the same doses, except for the 15 mg version.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Vipin Garg, Altimmune CEO

Al­tim­mune’s shares halved af­ter in­ter­im look at PhII weight loss drug da­ta

Altimmune’s attempt to catch up to Novo Nordisk and Eli Lilly’s GLP-1 drugs hit an investor snag Tuesday after the biotech shared interim Phase II weight loss data.

The Maryland biotech’s pemvidutide is a GLP-1/glucagon dual receptor agonist meant to activate GLP-1 receptors to squash appetite and glucagon to ramp up energy use. The 2.4 mg dose showed a placebo-adjusted weight loss of 9.7% at week 24 of 48, which Jefferies analysts said would be comparable to Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Mounjaro).

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Harpreet Singh, Immatics CEO

Im­mat­ics an­nounces mul­ti­ple pipeline changes with lat­est fi­nan­cial re­sults

The T-cell biotech Immatics is looking to make some changes to its pipeline.

Immatics released its 2022 financial results on Tuesday and announced that it’s planning to discontinue its program for IMA201, an experimental cell therapy for solid tumors that express the antigens known as MAGE4/8. It plans to shift focus to IMA401, a TCR bispecific which goes after the same target.

The German-based biotech said it will treat the remaining patients enrolled in the program before the discontinuation. No other reasons were given for the discontinuation. Endpoints News reached out to Immatics for more details but did not receive a response by press time.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

FTC says patent bat­tle over Parkin­son's drug could have 'sig­nif­i­cant im­pli­ca­tion­s' for pa­tients

The Federal Trade Commission has gotten involved in a patent feud over Supernus’ Parkinson’s drug Apokyn, a case the agency said may have ‘‘significant implications” for patients who rely on the drug.

Sage Chemical won the first generic approval for its Apokyn formulation (also known as apomorphine hydrochloride injection) back in 2022. The non-ergoline dopamine agonist is approved to treat Parkinson’s symptoms during “off episodes,” such as difficulty moving, tremors and intense cramping. However, regulators specified that the approval pertained to the generic drug cartridges only, not the injector pen required for administration.